Boston Scientific (NYSE:BSX) Stock Sale Reported by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $50,001 and $100,000 in Boston Scientific stock on September 4th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Boston Scientific Stock Down 1.5%

BSX traded down $0.65 on Tuesday, reaching $43.46. 2,087,721 shares of the company traded hands, compared to its average volume of 18,718,625. The company has a market cap of $62.99 billion, a price-to-earnings ratio of 17.63, a PEG ratio of 1.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The stock’s 50 day moving average price is $46.97 and its 200-day moving average price is $52.24. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $105.65.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the firm earned $0.75 EPS. The company’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on BSX shares. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Canaccord Genuity Group dropped their price objective on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Piper Sandler restated an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a research report on Wednesday, July 29th. Finally, Weiss Ratings lowered Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Twenty-three equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $70.19.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael Mahoney bought 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director David Habiger purchased 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Large investors have recently added to or reduced their stakes in the company. Kingsview Wealth Management LLC increased its position in Boston Scientific by 2.4% in the 4th quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock valued at $578,000 after acquiring an additional 142 shares in the last quarter. Paragon Private Wealth Management LLC raised its holdings in Boston Scientific by 1.2% during the 4th quarter. Paragon Private Wealth Management LLC now owns 15,950 shares of the medical equipment provider’s stock worth $1,521,000 after purchasing an additional 185 shares during the last quarter. GraniteShares Advisors LLC boosted its stake in shares of Boston Scientific by 1.5% in the 1st quarter. GraniteShares Advisors LLC now owns 13,599 shares of the medical equipment provider’s stock valued at $853,000 after purchasing an additional 195 shares during the last quarter. Avantax Planning Partners Inc. boosted its stake in Boston Scientific by 4.0% in the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock valued at $329,000 after acquiring an additional 201 shares during the last quarter. Finally, J.W. Cole Advisors Inc. grew its holdings in Boston Scientific by 2.4% during the 4th quarter. J.W. Cole Advisors Inc. now owns 8,768 shares of the medical equipment provider’s stock worth $836,000 after acquiring an additional 202 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.